AbbVie’s upadacitinib missed the primary endpoint in Phase 3 SELECT-TAK, despite fewer relapses than placebo in patients with Takayasu arteritis.
Written By: Charvi Kalal, PharmD
Reviewed By: Pharmacally Editorial Team
An abstract published in The Lancet Rheumatology reports results from SELECT-TAK, a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial evaluating AbbVie’s oral Janus kinase (JAK) inhibitor upadacitinib in patients with Takayasu arteritis. Although the primary endpoint was not met, the time-to-relapse analysis numerically favoured upadacitinib, with fewer observed relapses and a longer median time to relapse than placebo.
The findings provide a potential efficacy signal in patients with relapsing Takayasu arteritis who had previously experienced difficulties with glucocorticoid tapering, but do not establish a statistically significant treatment benefit.
SELECT-TAK Trial Design and Patient Population
SELECT-TAK was conducted at 31 tertiary referral centres and university hospitals across six countries: Japan, China, South Korea, Argentina, Brazil and Türkiye. Between March 3, 2020, and December 5, 2023, the trial enrolled 59 patients aged 18 years or older, with eligibility extended to those aged 15 years or older in Japan.
Participants had Takayasu arteritis, at least one unsuccessful attempt at glucocorticoid tapering, and a relapse within 12 weeks before baseline. Patients were required to be in remission on a stable glucocorticoid dose of no more than 1 mg/kg/day for at least one week before baseline.
Patients were randomly assigned in a 1:1 ratio to receive oral upadacitinib 15 mg once daily (n=30) or placebo (n=29). Concomitant immunomodulatory treatments other than corticosteroids were excluded under the trial eligibility criteria. Both groups followed a standardised glucocorticoid taper beginning at week 4, with dose reductions of 10% per week to at least 0.1 mg/kg/day.
The primary endpoint was time to first relapse during the double-blind period. The trial registry specified an event-driven endpoint assessment targeting 40 relapse events, estimated to require approximately 52 months. This was the planned endpoint observation timeframe, not a fixed treatment duration for every participant.
Relapse was defined by qualifying signs and symptoms across five categories: objective systemic symptoms, subjective systemic symptoms, elevated inflammatory markers, vascular signs and symptoms, or ischaemic symptoms. Criteria had to be met in at least two categories at two consecutive assessments, or at one assessment when urgent treatment escalation was required.
The registered secondary endpoints included time to first relapse according to the Kerr criteria and time to worsening of vascular imaging findings assessed by computed tomography angiography (CTA).
Upadacitinib Numerically Reduced Relapse Events but Missed the Primary Endpoint
The primary endpoint was not met with upadacitinib (hazard ratio [HR] 0.52, 95% CI 0.24–1.12; log-rank p=0.045). Nevertheless, observed relapse events numerically favoured upadacitinib.
Relapse occurred in 11 of 30 patients (37%) receiving upadacitinib compared with 18 of 29 patients (62%) receiving placebo. Median time to relapse was also longer with upadacitinib at 107.9 weeks (95% CI 20.1–not estimable), compared with 20.1 weeks (95% CI 12.0–127.1) with placebo.
Although these findings indicate fewer and later observed relapses in the upadacitinib group, they do not establish a statistically significant treatment benefit. The investigators concluded that the primary endpoint did not meet the prespecified statistical significance threshold, despite the reported log-rank p-value of 0.045. The hazard ratio confidence interval also included 1, reflecting uncertainty around the estimated treatment effect.
Safety Findings
Nine serious adverse events were reported in the upadacitinib group compared with four in the placebo group. No deaths occurred in either treatment group.
The authors reported that no new clinically meaningful safety events were identified. However, the numerical difference in serious adverse events warrants consideration. The published abstract does not provide a detailed breakdown of these events, the number of affected patients or adverse events leading to treatment discontinuation, limiting a comprehensive comparative safety assessment.
Clinical Significance
SELECT-TAK investigated a clinically challenging population with relapsing Takayasu arteritis and a history of unsuccessful glucocorticoid tapering. The numerical differences in relapse events and median time to relapse provide a signal warranting further investigation, particularly in the context of efforts to maintain disease remission while reducing glucocorticoid exposure.
However, the trial’s failure to meet its primary endpoint, small sample size and wide confidence intervals limit the conclusions that can be drawn. Most participants were female (90%) and Asian (75%), including 61% who were Japanese, which also warrants consideration when interpreting the findings across broader patient populations.
The registered secondary endpoints may provide additional information about clinical relapse and vascular imaging progression, but their results are not reported in the available abstract. The authors concluded that further exploration of upadacitinib in refractory Takayasu arteritis is warranted. The abstract does not announce a subsequent trial or regulatory submission for this indication.
Reference
Nakaoka Y, et al. Efficacy and safety of upadacitinib in Takayasu arteritis (SELECT-TAK): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Rheumatology. Published November 17, 2026. doi:10.1016/S2665-9913(26)00254-7.
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants with Takayasu Arteritis (TAK) (SELECT-TAK), ClinicalTrials.gov ID NCT04161898
About the Writer
Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.
